Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers
Open Access
- 30 October 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 22 (1), 1-11
- https://doi.org/10.1186/s13054-018-2220-9
Abstract
Given the pathophysiological key role of the host response to an infection rather than the infection per se, an ideal therapeutic strategy would also target this response. This study was designed to demonstrate safety and feasibility of early therapeutic plasma exchange (TPE) in severely ill individuals with septic shock. This was a prospective single center, open-label, nonrandomized pilot study enrolling 20 patients with early septic shock (onset < 12 h) requiring high doses of norepinephrine (NE; > 0.4 μg/kg/min) out of 231 screened septic patients. Clinical and biochemical data were obtained before and after TPE. Plasma samples were taken for ex-vivo stimulation of human umbilical vein endothelial cells (HUVECs) to analyze barrier function (immunocytochemistry and transendothelial electrical resistance (TER)). Cytokines were measured by cytometric bead array (CBA) and enzyme-linked immunosorbent assays (ELISAs). An immediate response was defined as > 20% NE reduction from baseline to the end of TPE. TPE was well tolerated without the occurrence of any adverse events and was associated with a rapid reduction in NE (0.82 (0.61–1.17) vs. 0.56 (0.41–0.78) μg/kg/min, p = 0.002) to maintain mean arterial pressure (MAP) above 65 mmHg. The observed 28-day mortality was 65%. Key proinflammatory cytokines and permeability factors (e.g., interleukin (IL)-6, IL-1b, and angiopoietin-2) were significantly reduced after TPE, while the protective antipermeability factor angiopoietin-1 was not changed. Ex-vivo stimulation of HUVECs with plasma obtained before TPE induced substantial cellular hyperpermeability, which was completely abolished with plasma obtained after TPE. Inclusion of early septic shock patients with high doses of vasopressors was feasible and TPE was safe. Rapid hemodynamic improvement and favorable changes in the cytokine profile in patients with septic shock were observed. It has yet to be determined whether early TPE also improves outcomes in this patient cohort. An appropriately powered multicenter randomized controlled trial is desirable. Clinicaltrials.gov, NCT03065751. Retrospectively registered on 28 February 2017.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DA1209/4-3)
This publication has 26 references indexed in Scilit:
- Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012Intensive Care Medicine, 2013
- Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*Critical Care Medicine, 2012
- Drotrecogin Alfa (Activated) in Adults with Septic ShockThe New England Journal of Medicine, 2012
- Angiopoietin-1 Requires IQ Domain GTPase-Activating Protein 1 to Activate Rac1 and Promote Endothelial Barrier DefenseArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Clinical review: Blood purification for sepsisCritical Care, 2011
- Immunotherapy for Sepsis — A New Approach against an Ancient FoeThe New England Journal of Medicine, 2010
- Comparison of Dopamine and Norepinephrine in the Treatment of ShockThe New England Journal of Medicine, 2010
- Vasopressin versus Norepinephrine Infusion in Patients with Septic ShockThe New England Journal of Medicine, 2008
- Plasma exchange as rescue therapy in multiple organ failure including acute renal failure*Critical Care Medicine, 2003
- The Pathophysiology and Treatment of SepsisThe New England Journal of Medicine, 2003